Cargando…

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient

Detalles Bibliográficos
Autores principales:	Bregigeon, Sylvie, Menard, Amélie, Faucher, Olivia, Tamalet, Catherine, Solas, Caroline, Obry-Roguet, Véronique, Poizot-Martin, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315977/ http://dx.doi.org/10.1186/1742-4690-7-S1-P59

Ejemplares similares

Educational intervention and HIV infection: preliminary results
por: Bregigeon, Sylvie, et al.
Publicado: (2010)

Changes in immune activation in the T Cell compartments of HIV HCV coinfected patients during PEG IFN RBV treatment
por: Menard, Amélie, et al.
Publicado: (2012)

A Case of Undiagnosed HIV Infection in a 57-Year-Old Woman with Multiple Myeloma: Consequences on Chemotherapy Efficiency and Safety
por: Poizot-Martin, I., et al.
Publicado: (2016)

A multidisciplinary staff for the optimisation of therapy in HIV-infected patients treated for cancer
por: Daigre, Julie, et al.
Publicado: (2012)

Risk factors associated with overweight and obesity in HIV-infected people: Aging, behavioral factors but not cART in a cross-sectional study
por: Obry-Roguet, Véronique, et al.
Publicado: (2018)

HIV-1 Infection and First Line ART Induced Differential Responses in Mitochondria from Blood Lymphocytes and Monocytes: The ANRS EP45 “Aging” Study
por: Perrin, Sophie, et al.
Publicado: (2012)

Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
por: Palich, Romain, et al.
Publicado: (2021)

Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model
por: Despiegel, Nicolas, et al.
Publicado: (2012)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial
por: Lafeuillade, Alain, et al.
Publicado: (2014)

HIV Protease Inhibitors Do Not Cause the Accumulation of Prelamin A in PBMCs from Patients Receiving First Line Therapy: The ANRS EP45 “Aging” Study
por: Perrin, Sophie, et al.
Publicado: (2012)

Correction: HIV Protease Inhibitors Do Not Cause the Accumulation of Prelamin A in PBMCs from Patients Receiving First Line Therapy: The ANRS EP45 “Aging” Study
por: Perrin, Sophie, et al.
Publicado: (2013)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma
por: Poizot-Martin, Isabelle, et al.
Publicado: (2022)

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Drug interactions in the elderly HIV-infected patient
por: Coroiu, C, et al.
Publicado: (2010)

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
por: Poizot-Martin, Isabelle, et al.
Publicado: (2015)

Safety and efficacy of maraviroc (MVC) combined with multiple different therapeutic agents in highly treatment-experienced (TE) patients in Brazil
por: Furtado, JJD, et al.
Publicado: (2010)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015
por: Poizot‐Martin, I., et al.
Publicado: (2020)

Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study
por: Portsmouth, S, et al.
Publicado: (2010)

Determinants of Second Primary Cancer Type in Survivors of Virus-Related and Non-Virus-Related Cancer Living With HIV in the French Dat’AIDS Cohort
por: Poizot-Martin, Isabelle, et al.
Publicado: (2021)

Prevalence and Spectrum of Second Primary Malignancies among People Living with HIV in the French Dat’AIDS Cohort
por: Poizot-Martin, Isabelle, et al.
Publicado: (2022)

First-line cART regimen impacts the course of CD8(+) T-cell counts in HIV-infected patients that achieve sustained undetectable viral load.
por: Poizot-Martin, Isabelle, et al.
Publicado: (2016)

Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort
por: Obermeier, MJ, et al.
Publicado: (2010)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
por: Kramer, Victor, et al.
Publicado: (2014)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

Diagnostic algorithm for Primary Ciliary Dyskinesia: recommendations of the French National Centre for Rare Respiratory Diseases
por: Blanchon, S, et al.
Publicado: (2012)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France
por: Rojas Rojas, Teresa, et al.
Publicado: (2022)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced
por: Cipriani, S, et al.
Publicado: (2012)

Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT’AIDS cohort
por: Lions, C., et al.
Publicado: (2019)

Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc
por: Bernal, Enrique, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aj4dsl3bqfeed2fqssbj0rsbst